Palvella Therapeutics Inc (PVLA) Stock Price, Quote & News

Company Profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treat...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 253 1461

Website: palvellatx.com

Address:

353 W. Lancaster Avenue, Suite 200, Wayne, United States

KatsuDonny Aug. 5 at 5:47 AM

$PVLA should see at least 25-30 percent upside in shareprice this year.

0 · Reply

EarningsInsider Aug. 4 at 1:46 PM

https://www.marketbeat.com/earnings/reports/2026-8-4-palvella-therapeutics-stock/ $PVLA Palvella Therapeutics Earnings Transcript

0 · Reply

StocktwitsEarnings Aug. 4 at 1:20 PM

$PVLA Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$1.52 down -76.74% YoY

0 · Reply

focafoca99 Jul. 28 at 11:52 AM

$PVLA opened its Q2 2026 results and corporate update call for Aug 4, 2026.

0 · Reply

Jonita Jul. 21 at 6:08 PM

$PVLA 💪💪💪💪💪💣

0 · Reply

notreload_ai Jul. 21 at 12:58 PM

$PVLA stock fell 21% Monday after FDA denied Breakthrough Therapy status for QTORIN. Analysts at BTIG view it as a short-term setback and maintain Buy rating with $215 price target. https://notreload.xyz/xy/pvla-drops-21-after-fda-snub-btig-says-buy/

0 · Reply

F15EAGLE1 Jul. 20 at 10:35 PM

$PVLA $PVLA Here is what triggered the selling today - FDA did not issue BTD for cVM - see the last bullet point They have BTD for mLM, which is under rolling NDA submission/ rolling review Plan to resubbmit the request for BTD for cVM with additional ph2 data

1 · Reply

JFais Jul. 20 at 9:50 PM

$PVLA added to DD list on today's gap down (will take me a while to get to it, several other names in queue first) Market didn't like that they failed to get Breakthrough Designation for cVM (have it for lead indication mLM) Bear points from Chat (ongoing discussion) well taken, including concerns on market penetration + overlap with systemic treatments like $RLAY's zovegalisib among others

0 · Reply

Kippy182 Jul. 20 at 8:59 PM

$PVLA not many shares

0 · Reply